Compare Incyte Corporation (INCY) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs IAC/Interactivecorp — how do they compare? Incyte Corporation trades at $112.97 (market cap $22.85B), while IAC/Interactivecorp trades at $41.13 (market cap $3.05B). The key difference: Incyte Corporation is far larger — about 7.5× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is more actively traded (931,019 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and IAC/Interactivecorp for 79 Days on average.
| INCY | PPLI | |
|---|---|---|
Market Cap | $22.85B | $3.05B |
Volume | 1,927,029 | 931,019 |
Sector | Health | Media |
52-Week High | $129.93 | $47.62 |
52-Week Low | $83.80 | $31.52 |
Typical Hold Time | 33 Days | 79 Days |
Enterprise Value | $18.35B | $3.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
PPLI trades at $40.94, up 0.86% with bullish technical signals and strong analyst support (71% buy ratings). The stock shows mixed fundamentals with a low P/E of 6.92 and P/B of 0.6, but recent earnings volatility includes two misses and one beat. Recent MGM takeover speculation has driven significant price movement, with shares surging 11.3% following acquisition discussions.
Investment outlook balances attractive valuation metrics against operational challenges. The company faces revenue decline from $5.2B (2022) to $2.4B (2025) and negative net income in 2025, though 2026 projections show recovery. Key risks include media industry headwinds and execution uncertainty, while MGM deal potential offers upside catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
